The Agri-Cortex
RESEARCH · JULY 2026

The analysis.

An independent read on agri-food biomanufacturing — market data, the four themes we track, the technology behind smart proteins, and our latest white paper. Figures are dated and cited; where sources conflict, we say so.

ON THIS PAGEMarket viewThemes in depthTechnologyExplainersWhite paper
MARKET VIEW

A snapshot of the market.

An independent read on agri-food biomanufacturing, compiled from public industry sources. Estimates differ between sources, so figures here are indicative and dated — read them as direction, not precision.

01

The global picture

Market size, the plant-based plateau, where 2024 investment landed, and the vertical-farming adjacency.

SMART PROTEINS · MARKET SIZE
≈ $36B by 2030
Alternative-protein market
02040202420272030

The broad alternative-protein market keeps compounding at a high-single-digit rate (≈8–9% CAGR), even as its sub-sectors move at very different speeds.

Sources: ResearchAndMarkets / Arizton; Grand View; Precedence (2024–2030). 2024 estimates range ≈ $16–22B. $ billions.
ALTERNATIVE MEAT · GROWTH
$29B in 2023
Plant-based retail — a plateau
2022$28B2023$29B

After years of rapid growth, plant-based retail has largely flattened — global sales up only slightly, and US dollar sales down ≈ 4% in 2024.

Sources: GFI State of the Industry (2023); SPINS / GFI (2024). Global retail: plant-based meat, seafood & dairy.
SECTORS · 2025 INVESTMENT
$881M total
Where the capital went
Plant-based$450MFermentation$357MCultivated$74M

In 2025, total funding fell ~20% to $881M — below $1B for the first time since 2018. Plant-based led on headline value, but only because of a single $100M Beyond Meat debt round; fermentation fell ~43% and cultivated ~48%. Fermentation then took $121M of the $162M raised in Q1 2026.

Source: Good Food Institute, 2026 State of the Industry. $ millions, global private investment.
VERTICAL FARMING · OUTLOOK
≈ 20% CAGR
Vertical / indoor farming
01428202420272030

Controlled-environment and vertical farming remain a fast-growing adjacency, though energy costs and unit economics still gate profitability.

Sources: Grand View; Polaris; Mordor (2024–2026). Estimates vary widely. $ billions.
02

India vs Europe

A large, maturing market beside a fast-emerging one — with illustrative scenarios to 2030.

INDIA vs EUROPE · SMART PROTEIN

A large, maturing market — and a fast-emerging one.

EUROPE
≈ $5.8B
Plant-based food retail, 6 major markets (2023)
  • Up 5.5% in 2023; growth now mid-single-digit and plateauing in some markets
  • Germany is the largest (≈ €2.2B, ~40% of the six-market total)
  • A large, relatively mature market approaching price parity in several categories
INDIA
≈ $0.8B
Alternative-protein market (2023) — ~5% of the global total
  • Projected ≈ $1.5B by 2030 (≈9% CAGR); smart-protein segment targeted at $1.5B–$4.2B by 2030 (scenario range; upper bound includes exports)
  • 100+ startups across plant-based, fermentation & cultivated; DBT / BIRAC & BioE3 support
  • Small today but early on its growth curve — and ≈ 90% of inputs are still imported
MARKET SIZE · 2023 (US$ B)
Europe$5.8BIndia$0.8B
2030 OUTLOOK · ILLUSTRATIVE SCENARIOS
INDIA
BASE~$1.5B — broad alt-protein at ~9% CAGR (Grand View)
UPSIDE$1.5B–$4.2B — smart-protein segment scaling (GFI India × Deloitte scenario range; $4.2B is the high-growth case, incl. exports), if localization, cost-down & regulatory clarity land
EUROPE
BASE~$7–8B — mid-single-digit growth from ~$5.8B (2023)
UPSIDEfaster if EU novel-food approvals accelerate; muted if EFSA timelines persist
Scenarios are illustrative, not forecasts — outcomes hinge on cost-down, input localization and regulatory pace.

Europe is among the world's largest and most mature alternative-protein markets — roughly US$5.8B in 2023 (≈€5.4B across six major markets), now growing in the mid-single digits and flat-to-modest as of 2025–26. India's market is far smaller today (≈US$0.8B, ~5% of the global total) but sits much earlier on its curve: broad alternative-protein revenue is projected to reach ≈US$1.5B by 2030 (≈9% CAGR), while the narrower "smart protein" segment is projected to scale from ≈US$42M to US$1.5B–$4.2B by 2030 on policy tailwinds (DBT/BIRAC, the BioE3 policy) and a deep manufacturing and STEM base. With ≈ 90% of inputs still imported, India's largest gap — localized biomanufacturing — is also its clearest opportunity.

Sources: GFI Europe / Circana (2023, plant-based food retail, six markets); Grand View Research (India alternative protein, 2023–2030); GFI India × Deloitte (India smart protein, →2030). Definitions and scopes differ between sources, so this comparison is directional rather than like-for-like.

Figures are drawn from third-party market-research and industry reports and are provided for general analysis only. They are not forecasts, endorsements, or investment advice.

IN DEPTH

The four themes we track.

A closer read on the forces shaping agri-food biomanufacturing — the economics, the localization opportunity in India, where demand actually sits, and how capital and policy are moving.

Cost & economics
Price is the gatekeeper — and each pillar runs on its own clock.

Alternative proteins scale only as they close the gap on price. Plant-based meat still sells at a clear premium — on average roughly twice the price of conventional beef, and more versus pork and chicken — and about a fifth of consumers name cost as the reason they don’t buy. The route to parity runs through cheaper feedstocks, food-grade inputs, and sheer scale, where every doubling of capacity tends to cut unit cost by 20–30%.

2–4× plant-based vs conventional meat (2× beef, 3× pork, 4× chicken)
~99% fall in cultivated-meat cost since 2013; recent methods near £5/lb
~2030 earliest cultivated cost-competitiveness (≈$2.92/lb); plant-based & fermentation sooner
Sources: GFI; Nature Food / Believer Meats (2024); McKinsey (2024). Figures indicative.
Localization for India
The biggest constraint — importing most inputs — is the biggest opportunity.

India is among the world’s largest pulse producers, yet imports the large majority of its alternative-protein raw material and lacks domestic protein-fractionation capacity. Localizing feedstocks — pulses, soy, pea, chickpea, millets — and pooling capital-heavy fermentation infrastructure is where cost, supply-chain resilience, and jobs converge. This is the core of India’s national biomanufacturing push.

~90% of alternative-protein inputs currently imported
16 hubs biomanufacturing hubs (500–1,000 L fermenters) planned under BioE3
₹42 cr Mohali BioFoundry for alt-protein scale-up (≈$4.5M)
Sources: GFI India; DBT / BioE3; industry reporting (2024–2026).
Applications & demand
Demand is real but uneven — led by dairy alternatives and flexitarians, not vegans.

In Europe, plant-based milk and drinks lead (about 41% of category sales), with meat second; household penetration keeps rising and flexitarians now make up roughly a third of consumers. India’s market is younger but broad — hundreds of products and a fast-growing food-service presence — with taste, price, and perceived ‘naturalness’ the main barriers to repeat purchase.

41% plant-based milk share of EU plant-based sales (≈€2.2B)
~31% Europeans identifying as flexitarian (up ~10 pts since 2023)
377 / 73 smart-protein products / brands available in India
Sources: GFI Europe / Circana (2023–24); GFI India (2024).
Players & policy
Capital is rotating toward fermentation — and policy, in India, is now a tailwind.

Global investment cooled to $881M in 2025 — the first sub-$1B year since 2018. Plant-based led on headline value ($450M, flattered by one $100M debt round) while fermentation fell ~43% to $357M; fermentation then took $121M of the $162M raised in Q1 2026 as the field tilts toward B2B ingredients rather than finished products. Policy is increasingly decisive: India’s BioE3 policy names smart proteins a priority theme, backed by DBT and BIRAC funding, while regulatory pathways — FSSAI in India, and approvals already granted in Singapore and the US — continue to mature.

$881M 2025 private investment — fermentation $357M, and $121M of $162M in Q1 2026
BioE3 India policy (Aug 2024) naming smart proteins a priority
$300B India bioeconomy target by 2030 under BioE3
Sources: GFI 2026 State of the Industry; DBT / BioE3 & Bio-RIDE (2024).
DEEP DIVE
How smart proteins are actually made
The methods, the trade-offs, and where India and Europe really stand — the science behind the market. Click to explore →

Smart proteins are made mainly by precision fermentation — engineered microbes brewing a target protein — and by cell cultivation. Two engineering paradigms are racing to make them cheap enough to matter, and increasingly merging.

HIGH-THROUGHPUT · EXPERIMENTAL
Explore widely, let the data decide
  • Directed evolution, automated library screening, microfluidic cell sorting, micro-bioreactors and Design-of-Experiments process tuning.

Strength: works without full mechanistic insight — proven for enzymes and production strains.

AI-LED · ADVANCED
Predict first, validate a focused set
  • AlphaFold and de novo design (RFdiffusion, ProteinMPNN), protein language models, ML-guided evolution, metabolic modelling; continuous, food-grade bioprocessing.

Strength: narrows the search and cuts wet-lab cycles — reaching designs screening would miss.

The catch — and the real bottleneck
  • High-throughput is capital-heavy, and lab-scale hits often fail to translate to production.
  • AI-led design needs large food-protein datasets that barely exist, and predicts structure far better than manufacturability, yield or taste.
  • Either way, the binding constraint is downstream — fermentation capacity, media and feedstock cost, energy and regulation. Meeting even a fraction of 2030 demand needs ≈ 20× today’s global pharma fermentation capacity (McKinsey).
Recent advances — India & Europe
INDIA
  • Policy & build-out: BioE3 (2024) prioritises smart proteins; a National Biofoundry Network (2025) is scaling biomanufacturing — DBT funds labs, BIRAC funds startups.
  • On the ground: Phyx44, Zero Cow, StrainX ($13M) and Perfect Day–Zydus on fermentation; Biokraft, Clear Meat, Neat Meatt on cultivated. Edge: low capex/opex and a deep pharma base.
EUROPE
  • Science depth: Formo (DE) and Those Vegan Cowboys (BE/NL) pooling casein R&D; Formo raised €61M + €35M EIB; precision-fermentation funding ≈tripled to ≈€120M in 2024; ~88 of 186 global PF firms are European.
  • The brake: no major precision-fermented protein is EU-approved as of early 2026 — EFSA lags the US, though a proposed EU ‘Biotech Act’ aims to speed approvals.
WHAT THE FUTURE HOLDS

The two paradigms are converging into AI-native, ‘self-driving’ biofoundries that close the design–build–test–learn loop with robotics — and India is explicitly building them. The decisive levers are moving out of the lab: toward scale-up capacity, cheaper food-grade media, modular decentralised bioreactors and regulatory speed. Europe leads on science and strains; India is racing on policy, manufacturing and cost — and precision-fermentation players now target parity within the decade.

Sources: GFI; McKinsey; ProVeg / Food Fermentation Europe; Green Queen; DairyReporter; ThePrint; SiliconIndia; DBT / BioE3 (2024–2026). Independent synthesis of public reporting; technical detail is generalised.
EXPLAINERS · PLAIN LANGUAGE

The field, explained simply.

Short, illustrated, sourced guides to agri-food biomanufacturing — written so anyone can follow, and guided by Cortex. New explainers added over time.

EXPLAINER NO. 4 · JULY 2026 · INTERACTIVE BRIEFING

From broth to breakthrough

A deep dive into biomass fermentation — the branch of smart protein that grows whole microbes as food. Where it stands in 2025–26, why scale-up, not the science, is the bottleneck, and the frontier ideas turning CO₂, methane and crop stubble into protein.

  • 163+ fermentation companies worldwide — biomass is ~50% of microbial-protein output
  • The real barrier is the “valley of death”: downstream cost, not the molecule
  • Frontier: protein from air, stubble-to-protein, and mycelium meat scaffolds
  • A curated company landscape across India & Europe
Open the briefing →
● LIVE · BIOREACTOR Dive in →
Biomass fermentation — the oldest biotech, suddenly new again.
Field Guide · Interactive · Companion to No. 4

Meet the microbes

The briefing maps where biomass fermentation stands. This companion field guide introduces who actually does the work — fourteen production hosts, from a bread yeast to a vaccine-making leaf, each with an honest dossier of what it makes, how well, and who’s using it.

  • 14 real hosts — tap any character to open its dossier
  • Biomass vs precision fermentation, decoded
  • The same microbes across food, beauty, pharma & feed
Open the field guide →
◗ Interactive field guide Open →
Who actually makes
your protein?
14 hosts · 4 industries · a field guide with a sense of humour
EARLIER IN THE SERIES
INTERACTIVE
EXPLAINER NO. 3
JUNE 2026 · INTERACTIVE

The Unclosed Loop

India’s residue-to-protein circle leaks at six points. An interactive map of where value spills — what’s moved since the 2025 baseline, who’s sealing each gap, and what the five years to 2031 could close.

Open the interactive →
EXPLAINER NO. 2
MAY 2026 · DATA FEATURE

The Great Protein Reversal

Why Europe and India are solving the same problem from opposite ends — Europe racing to grow its own protein, India burning residue it could turn into value. With sourced comparison charts.

Read the explainer (PDF) →
EXPLAINER NO. 1
APRIL 2026 · PLAIN LANGUAGE

What are Smart Proteins?

The same protein your body already loves — grown a smarter way. What they are, how they differ from normal proteins, why they’re named “smart,” and why they matter now. No lab coat required.

Read the explainer (PDF) →
SMART-PROTEIN MARKET BRIEF · ONE PAGE

Where the value sits — and what has actually shipped.

The whole field on a single page: where 2025 capital went by route, what has cleared regulation in the EU and India, and how India and Europe divide the problem. Every figure dated and cited.

Read the one-page brief (PDF) →
PUBLICATION · WHITE PAPER · JULY 2026

India’s Agricultural Transformation

From Food Security to Food Systems Value

India has decisively solved the problem it set out to solve in 1965: calorie sufficiency. Foodgrain output hit a record 357.73 million tonnes in 2024–25 and the state distributes free grain to 81.35 crore people. The binding constraint has moved — from production to value, nutrition, and resilience. This paper examines what the government initiated, why, for whom, and where the sector is heading over the next five years.

  • Sufficiency is solved; value is not. Output rose 106 MT in a decade, yet ≈₹92,651 crore is lost post-harvest each year and storage covers barely a quarter of production.
  • The state is buying the future. Nine new missions in the 2025–26 Budget; PM Dhan-Dhaanya reaching 1.7 crore farmers in 100 districts; BioE3 targeting a $300B bioeconomy by 2030, with smart proteins a named priority.
  • Capital moved the other way. Agritech funding fell ≈ 25% to ≈$202M in 2025 even as forecasts point to ≈ 25% CAGR — a divergence that defines the cycle, and the opportunity.
  • Localization is the arbitrage. India imports ≈ 90% of its alternative-protein inputs; the smart-protein segment is projected to scale from ≈$42M to $1.5B–$4.2B by 2030 (scenario range).
Sources: Ministry of Agriculture & Farmers’ Welfare / PIB; Union Cabinet (PMGKAY); Union Budget 2025–26 & PRS India; ICRIER; EPW; DBT / BioE3; GFI India × Deloitte; Inc42 × StarAgri; Tracxn; NABCONS / MoFPI; FCI. Independent analysis · not investment advice.
357.73 MT
Record foodgrain output, 2024–25 (+8% YoY)
81.35 cr
People receiving free foodgrains (PMGKAY)
$28B
Projected agritech market by 2030 (~25% CAGR)
−25%
Agritech funding change in 2025 (≈$202M)
HOW THIS IS COMPILED

The Agri-Cortex synthesizes publicly available data from industry bodies (GFI, GFI India, GFI Europe), market-research firms, and government and regulatory sources (DBT / BioE3, EFSA), alongside company reporting. Figures are indicative, dated, and cited inline; definitions differ across sources, so cross-market comparisons are directional rather than like-for-like. Independent analysis, compiled from public sources. Not investment advice.

LAST REVIEWED
July 2026
PRIMARY SOURCES
GFI · GFI India · GFI Europe · Circana · Grand View · Deloitte · McKinsey · DBT / BioE3 · EFSA
↓ MARKET BRIEFING (PDF)
CONTACT

Contact.

For questions about this market-intelligence initiative — or to share a perspective on where agri-food biomanufacturing is heading — you're welcome to reach out.

◗ The Agri-Cortex brief

Read the shift before it’s obvious.

Sourced, dated intelligence on the India × Europe smart-protein economy — new briefings, tracker updates and the occasional field guide. No noise.

Independent analysis · not investment advice · unsubscribe anytime.